John Dickson

Fingerprint

Dive into the research topics where John Dickson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Article

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., Matthews, H., Dickson, J., Carroll, C., Patrick, A., Inches, J., Silverdale, M., Blackledge, B., Whiston, J., Hu, M. & Welch, J. & 17 others, Duncan, G., Power, K., Gallen, S., Kerr, J., Chaudhuri, K. R., Batzu, L., Rota, S., Jabbari, E., Morris, H., Limousin, P., Greig, N., Li, Y., Libri, V., Gandhi, S., Athauda, D., Chowdhury, K. & Foltynie, T., 4 Feb 2025, In: Lancet. 405, 10479, p. 627-636 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
4 Downloads (Pure)

John Dickson

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

John Dickson

Fingerprint

Collaborations and top research areas from the last five years

Research output

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial